Century Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.47 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 266.18M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Details
| Name | Century Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 78 |
| Founded | 2019 |
| Ipo Date | 2021-06-18 |
| Ceo | Brent Pfeiffenberger |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US15673T1007 |
| Cusip | 15673T100 |
| Cik | 1850119 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, Chief Executive Officer and Chairman |
| Dr. Gregory Russotti Ph.D. | Chief Technology and Manufacturing Officer |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Douglas Carr CPA | Senior Vice President of Finance and Operations, Principal Financial Officer and Secretary |
| Krista Kauppinen J.D., Ph.D. | Vice President, General Counsel and Head of Intellectual Property |
| Megan Bilson | Chief People Officer |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering |
| Elizabeth Devlin | Vice President and Head of Development |
Contact
| Address | 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania 19104, United States |
| Phone | 267 817 5790 |
| Website | https://www.centurytx.com |